The calendar officially turned to summer in the northern hemisphere, and the US Food and Drug Administration came in already sizzling hot with action. Here's your news in brief:
The biggest news of the week was the FDA's approval of AMAG Pharmaceuticals Inc.'s Vyleesi (bremelanotide), which became the second US-backed drug to treat hypoactive sexual desire disorder (HSDD)....